Kailera Therapeutics, Inc. (KLRA)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	n/a
Net Income	-148.96M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About KLRA

Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration. Our lead product candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2024
• Employees: 145
• Stock Exchange: NASDAQ
• Ticker Symbol: KLRA
• Website: https://www.kailera.com/